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Abstract
Purpose Penile carcinoma is a rare malignant neoplasm with a largely unknown molecular pathogenesis. Telomerase reverse 
transcriptase promoter (TERT-p) mutations have been detected in several types of human malignancies. The aim of this study 
was to investigate the presence of TERT-p mutations in penile squamous cell carcinomas (SCCs) and their associations with 
clinicopathologic features.
Methods In this retrospective study, Sanger sequencing was performed to detect TERT-p mutations in formalin-fixed par-
affin-embedded tissue samples from 37 patients with penile SCC, 16 patients with cutaneous SCC, and 4 patients with non-
neoplastic penile/skin tissue. The expression of  p16INK4a and Ki-67 was investigated via immunohistochemistry. Associations 
of TERT-p mutation with clinicopathological factors, immunohistochemical results, and clinical outcome were statistically 
analyzed.
Results Recurrent TERT-p mutations were identified in 18 out of 37 (48.6%) penile SCCs, including all 3 carcinoma in situ 
cases. TERT-p mutations were significantly more frequent in non-human papilloma virus (HPV)-related penile SCC types 
than in non-HPV-related penile SCC based on both histologic classification and  p16INK4a immunoreactivity. Furthermore, 
TERT-p mutation was associated with a low histologic grade, low mitotic count, absence of necrosis, low Ki-67/MIB-1 
labeling index, and absence of lymph node or distant metastasis.
Conclusion Our study shows TERT-p mutations are the most frequent somatic mutations in penile SCC. In addition, TERT-p 
mutations are far more frequent in non-HPV-related penile SCC than in HPV-related penile SCC, indicating TERT-p muta-
tions may have a role in tumorigenesis distinct from HPV-related penile SCC.
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Introduction
Penile carcinoma is a rare malignant neoplasm with an 
incidence of 1–4 per 100,000 in developing countries 
and is even rarer in developed countries (Rubin et  al. 
2001). Squamous cell carcinoma (SCC) and its histologic 
variants account for approximately 95% of all cases of 
penile carcinoma (Suarez-Bonnet et al. 2018). Pathologi-
cally, penile carcinomas are classified into two distinct 
groups based on clinicopathologic characteristics and an 
association with HPV infection: human papilloma virus 
(HPV)-related and non-HPV-related type (Mannweiler 
et al. 2013). HPV high-risk (HPV-HR) DNA is detected 
in 20–80% of penile carcinomas, and plays a role in the 
carcinogenesis of HPV-related penile SCC (Spiess et al. 
2016). The detection rates of HPV DNA vary depending 
on histologic subtypes (Cubilla et al. 2016). Unlike SCC 
of the uterine cervix, which is caused by HPV in 100% of 
cases, only about 1/3–1/2 of penile carcinomas are caused 
by transforming HPV infection. The non-HPV-related 
penile SCC develops in the background of chronic inflam-
matory skin diseases such as lichen sclerosus and lichen 
planus. HPV-HR16 is known to be the most prevalent 
HPV DNA type in HPV-related penile SCC (Rubin et al. 
2001). The viral oncogenes of HPV, E6 and E7, bind to the 
tumor-suppressor proteins p53 and RB, respectively, lead-
ing to their inactivation, thereby affecting the cell cycle 
and apoptosis and resulting in unchecked replication of 
DNA and continued cell proliferation (Spiess et al. 2016). 
Consequently,  p16INK4a protein, a cyclin-dependent kinase 
inhibitor, accumulates, which can be identified by  p16INK4a 
immunohistochemistry (Aumayr et al. 2013).
Along with technological advances in the past decade, 
genetic alterations in cancers have been extensively dis-
closed, ushering in a new era of precision medicine in 
cancer treatment (Baudino 2015). However, this has not 
been the case for penile cancer, as the underlying molec-
ular pathogenesis is yet to be elucidated, which is most 
likely due to the rarity of penile SCC. Accordingly, no 
standardized treatment or personalized medicine has been 
established for penile cancer (Kim et al. 2018).
The telomerase reverse transcriptase (TERT) gene 
encodes the catalytic subunit of telomerase that is respon-
sible for telomere lengthening at chromosomal ends 
(Vinagre et al. 2014). Normal somatic cells and benign 
tumor cells lack telomerase activity, whereas telomerase is 
active in germ cells and stem cells of self-renewing tissues 
(Gunes and Rudolph 2013), and is found to be reactivated 
in up to 90% of cancer cells (Kyo et al. 2008). Reacti-
vation of telomerase maintains the telomere length and 
enables cancer cells to evade senescence resulting from 
telomere shortening. Novel recurrent somatic mutations 
in the core promoter region of TERT were recently iden-
tified in ~ 70% of melanoma samples examined by next-
generation sequencing, which have now become the most 
frequently detected mutation in malignant melanoma 
(Horn et al. 2013; Huang et al. 2013). Subsequently, these 
mutations were also detected at high frequencies in several 
other human malignancies, including thyroid carcinoma, 
glioma, bladder carcinoma, hepatocellular carcinoma, 
and various types of non-melanoma skin cancers such as 
SCC and basal cell carcinoma (Arita et al. 2013; Allory 
et al. 2014; Chen et al. 2014a, b; Griewank et al. 2013; 
Liu et al. 2013a, b; Populo et al. 2014; Scott et al. 2014). 
By contrast, TERT promoter (TERT-p) mutations have not 
been detected or have been detected at very low frequency 
in malignant tumors of other organs (Cheng et al. 2015; 
Huang et al. 2013; van Nistelrooij et al. 2014). In addition, 
the clinical relevance of these mutations has been high-
lighted based on significant associations with poor patient 
outcome or adverse clinicopathologic parameters in vari-
ous cancers (Chen et al. 2014a, b; Kinde et al. 2013; Grie-
wank et al. 2014; Melo et al. 2014; Qu et al. 2014; Simon 
et al. 2015). TERT-p mutations create de novo binding 
sites for E-twenty-six (ETS) transcription factors (CCG 
GAA ) within the TERT-p region. An in vitro luciferase 
assay also showed that these mutations resulted in a two- 
to fourfold increase of TERT promoter activity (Huang 
et al. 2013). Despite continuing research on TERT-p muta-
tion in human cancers, including a recent study describing 
the varying frequency of TERT-p mutation in SCCs arising 
from various organs (Cheng et al. 2015), TERT-p mutation 
in penile SCC has not been investigated to date.
Therefore, the aim of the present study was to investigate 
the presence of TERT-p mutations in penile SCC, and their 
associations with clinicopathologic parameters, along with 
 p16INK4a and Ki-67/MIB-1 expression.
Methods
Case selection
The study was approved by the Institutional Review Boards 
(IRB) of Ajou University School of Medicine and Yonsei 
University Health System, and performed in accordance 
with the Declaration of Helsinki. Informed consent was 
waived by the IRB for this retrospective study. Thirty-seven 
formalin-fixed, paraffin-embedded penile carcinoma tis-
sues surgically resected from patients in the time period 
between 2000 and 2017 were retrieved from the archives 
of the Department of Pathology of Ajou University School 
of Medicine (23 cases) and the Department of Pathology of 
Yonsei University College of Medicine (14 cases) based on 
the availability of tissue blocks or slides for histopathologic 
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analyses and DNA extraction. Among the 37 cases, there 
were three cases of carcinoma in situ (CIS) included. In 
addition, 16 cases of cutaneous SCC and 4 samples of non-
tumor skin or penile tissue were used as positive and nega-
tive controls, respectively, for TERT-p sequencing.
DNA extraction and direct sequencing
The tumors were manually dissected from 10-μm sections 
of formalin-fixed, paraffin-embedded tissues. Genomic DNA 
was extracted using the QIAamp kit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s instructions. Poly-
merase chain reaction (PCR) amplification of the TERT pro-
moter region was performed using the primer pair hTERT_F 
(CAC CCG TCC TGC CCC TTC ACC TT)/hTERT_R (CAG 
CGC TGC CTG AAA CTC), generating an expected 304-
bp product. The cycling conditions for PCR amplification 
were 95 ℃ for 2 min for denaturation, and 35 cycles of 95 ℃ 
denaturation for 30 s, 60 ℃ annealing for 30 s, and 72 ℃ 
elongation for 40 s. PCR products were confirmed by gel 
electrophoresis. Direct sequencing of both strands was per-
formed using a BigDye terminator v3.1 cycle sequencing 
kit (Applied Biosystems, Foster City, CA, USA) on an ABI 
3500XL genetic analysis system (Applied Biosystems).
Clinicopathologic features
All hematoxylin and eosin-stained slides from the tumors 
were reviewed independently by two pathologists who were 
blinded to other clinical and genetic information. Clinical 
data were collected from the medical records. The factors 
investigated were as follows: histologic subtype, grade, pres-
ence and type of penile intraepithelial neoplasia (PeIN), 
lymphovascular invasion, perineural invasion, ulceration, 
tumor thickness, necrosis, mitotic count, koilocytosis, 
acantholysis, tumor-infiltrating lymphocytes, intraepithe-
lial neutrophilic microabscess, peripheral tumor budding 
(Shimizu et al. 2018), tumor size, gross type, patient age, 
stage, lymph node or distant metastasis, and patient survival 
(Online Resource 1–3). Histologic subtype was classified 
into HPV-related type and non-HPV-related type according 
to the World Health Organization guidelines 2016 (Cubilla 
et al. 2016). A mixed HPV-related and non-HPV-related type 
was considered a HPV-related type for statistical analyses. 
The mitotic count was calculated from 10 contiguous high-
power fields located in the most mitotically active tumor 
region.
Immunohistochemistry for  p16INK4a and Ki‑67
Immunohistochemical staining for  p16INK4a and Ki-67 was 
performed on one representative block of all samples on 
a BenchMark XT autostainer (Ventana Medical Systems, 
Tucson, AZ, USA) according to the manufacturer’s protocol 
using a ready-to-use mouse monoclonal  p16INK4a antibody 
(CINtec p16 Histology, clone E6H4, Sedona, USA) and an 
anti-human mouse monoclonal Ki-67 antibody (1:100, clone 
MIB-1, DAKO, Copenhagen, Denmark). Only strong con-
tinuous staining of  p16INK4a was considered positive. Weak 
or spotty, patchy, and discontinuous staining was considered 
negative (Katzenellenbogen 2017a, b). For the Ki-67 stain, 
any distinct nuclear staining was recorded as positive. The 
Ki-67 (MIB-1) labeling index, defined as the percentage of 
positively stained tumor cells, was measured by computer-
assisted manual counting of at least 1000 tumor nuclei from 
the area of maximal labeling using Image-Pro Plus 4.5 
software.
Statistical analyses
Statistical analyses were performed using SPSS v22.0 (SPSS 
Inc., Chicago, IL, USA). The relation between TERT-p 
mutation and clinicopathologic parameters was evaluated 
using the χ2 test or Fisher’s exact test and the Mann–Whitney 
U test for categorical and continuous variables, respectively. 
Kaplan–Meier survival analysis and the log-rank test were 
used to analyze the prognostic effect of TERT-p mutation in 
terms of both disease-free survival (DFS) and overall sur-
vival (OS). Univariate and multivariate regression analyses 
were performed using the Cox proportional hazards model. 
A P value < 0.05 was considered significant. We conducted 
a power analysis for determining an appropriate sample size 




The age at diagnosis for the included patients was 
65.97 ± 12.18 years (range 40–87 years). Of the 37 penile 
SCCs, 17 were HPV-related type and 20 were non-HPV-
related type. Follow-up data were available for all 37 cases, 
and the follow-up period ranged from 4 months to 13.8 years 
(median 80.47 months). Seven patients died of the disease 
(Table 1).
TERT‑p mutations are frequent in penile SCC
Of the 37 penile SCCs, including the 3 cases of CIS, 18 cases 
(48.6%) harbored TERT-p mutations, including c.-146 C > T, 
c.-124C > T, and c.-124 C > A. All three CIS tumors har-
bored the c.-146 C > T mutation. Ten (62.5%) of the 16 skin 
SCCs had TERT-p mutations, which were located at posi-
tions c.-146 C > T, c.-124C > T, and c.-139_-138CC > TT 
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(Online Resource 4). The four negative control samples 
(non-neoplastic penile or skin tissue) all showed the wild-
type TERT-p sequence (Table 2).
Correlation of TERT‑p mutation status 
with clinicopathologic parameters
To explore potential associations between TERT-p mutation 
status and clinicopathologic parameters, statistical analyses 
were performed on the 24 invasive SCCs, excluding the 
three CIS cases. TERT-p mutations were more frequent 
in non-HPV-related type than in HPV-related type penile 
SCCs (13/20, 86.7% vs 2/14, 13.3%; p = 0.005). In line with 
this finding, TERT-p mutations correlated with the presence 
of differentiated PeIN, which is a precursor lesion associ-
ated with non-HPV-related type penile SCC (p = 0.005). 
TERT-p mutations were also more frequent in tumors with 
a lower histologic grade (p = 0.036), lower mitotic activity 
(p = 0.001), absence of necrosis (p = 0.045), larger tumor 
size (p = 0.045), and absence of lymph node or distant 
metastasis (p = 0.020) (Table 3).
Correlation of TERT mutation status with  p16INK4a 
and MIB‑1 immunohistochemistry
p16INK4a positivity was more frequent in TERT-p wild-type 
tumors (12/19, 63.2%) than in TERT-p mutant tumors (1/15, 
6.7%; p = 0.001), which is consistent with the above result 
that TERT-p mutations were more frequent in non-HPV-
related type than in HPV-related type penile SCC. In addi-
tion, the MIB-1 labeling index was significantly higher in 
TERT-p wild-type tumors (45.26 ± 19.38) than in TERT-p 
mutant tumors (31.80 ± 11.89; p = 0.014; Fig. 1).
Effects of TERT‑p mutations on prognosis of patients 
with penile SCC
We performed a power analysis to estimate the adequacy 
of sample size for Cox regression analysis in our study. 
A sample size of 34 subjects (wild group = 19, mutant 
group = 15) was determined to be optimal with 94.90% sta-
tistical power, a significance level of p < 0.05, and hazard 
ratio = 0.101(= 1/9.86). As shown in Fig. 2, patients with 
TERT-p-mutated tumors showed significantly longer DFS 
compared with that of patients with TERT-p wild-type 
tumors (p = 0.009). However, there was no difference in 
OS between patients with TERT-p-mutated and wild-type 
tumors (data not shown). A significant positive correlation 
between TERT-p mutation and DFS was confirmed by the 
univariate Cox regression analysis (hazard ratio 0.10, 95% 
CI 0.01–0.82). However, in the multivariate Cox regression 
analysis, TERT-p mutation status was not an independent 
factor affecting DFS (Table 4).
Table 1  Summary of patient characteristics
SD standard deviation, AJCC the American Joint Committee on Can-
cer
a The three cases of carcinoma in situ were included
Characteristics N = 37
Age at diagnosis (years)
 Mean ± SD 65.97 ± 12.18
 Range 40–87
Tumor size (cm)
 Mean ± SD 3.59 ± 2.43
 Range 1–14
Histologic type (no. of patient)
 HPV-related 17
 Non-HPV-related 20





Grade (no. of patient)
 1 (well differentiated) 10
 2 (moderately differentiated) 9
 3 (poorly differentiated) 18
Gross type (no. of patient)
 Superficial  spreadinga 8
 Verrucous 13
 Vertical 16

















Clinical outcome (no. of patient)
 Alive 22
 Died of disease 7
 Died of other cause 5
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Discussion
We here provide the first report of TERT-p mutation and 
its clinicopathologic significance in penile SCC. TERT-
p mutations were detected at a high frequency (48.6%) 
in penile SCC, which, to our knowledge, are the most 
frequent mutations in penile SCC described to date (Fer-
randiz-Pulido et al. 2015). Indeed, the majority of recur-
rent mutations reported in penile SCC are of low incidence 
(less than 10%) (Ferrandiz-Pulido et al. 2015; Wang et al. 
2019). Notably, out of 18 cases with TERT-p mutations, 
14 were c.-146 C > T and 3 were c.-124 C > T. These are 
known as mutation hotspots that have been reported to be 
the most common recurrent mutations in various organs 
and tend to be mutually exclusive, with two exceptions 
in which both mutations were identified in two cases of 
breast cancer (Huang et al. 2013). The remaining TERT-p 
mutation detected in our study was c.-124C > A, which 
was found in both an excision and penectomy specimen 
of the same patient and was the only case of sarcomatoid 
carcinoma in our cohort. Histologically, the transitional 
area from conventional SCC to sarcomatoid carcinoma 
was included in this sarcomatoid carcinoma case. The c.-
124C > A mutation was previously reported in one mam-
mary phyllodes tumor, as well as in urothelial carcinoma, 
hepatocellular carcinoma, and glioma (Yoshida et  al. 
2015).
The mutation rate of TERT-p in cutaneous SCC, which 
was used as a positive control, is concordant with previ-
ous reports (Griewank et al 2013). Cheng et al. evaluated 
TERT-p mutations in SCCs from different anatomic sites, 
finding a mutation rate of 70% for both skin and urinary 
bladder SCCs, but only 20% for head and neck SCC, and 
no TERT-p mutations were identified in uterine cervix and 
lung cancer (Cheng et al. 2015). The authors suggested that 
this finding supports a hypothesis of different carcinogenesis 
mechanisms of SCCs from different anatomic sites. Penile 
SCC shows a similar frequency of TERT-p mutations to that 
reported for cutaneous SCC or urothelial cancer.
ETS transcription factors, whose binding sites are gener-
ated within the promoter region through TERT-p mutations, 
are upregulated by the mitogen-activated protein kinase 
(MAPK) pathway; therefore, TERT-p mutations may be 
associated with mutations in genes involved in the MAPK 
pathway (Horn et al. 2013). Indeed, tumors harboring TERT-
p mutation at high frequency, such as melanoma, thyroid 
papillary carcinoma, and glioma, are also well known for 
a high frequency of BRAF mutation. Furthermore, signifi-
cant coexistence of TERT-p and BRAF mutations, and their 
associations with adverse clinicopathological factors have 
been reported in some tumors, including papillary thyroid 
carcinoma and melanoma, suggesting that these coexist-
ing mutations reflect a unique mechanism to upregulate 
the expression of TERT, cooperatively contributing to the 
aggressiveness of these tumors (Macerola et al. 2015; Xing 
et al. 2014). Likewise, we speculated that other mutations 
might coexist and act cooperatively with TERT-p mutations 
in penile SCC.
There have been only a few studies conducted on genetic 
alterations in penile SCC, including data obtained through 
whole-exome sequencing (Ferrandiz-Pulido et al. 2015; 
Wang et al. 2019). In general, the detection rates are low in 
all cases (detection rates of 3–9%), the main mutated genes 
identified in penile SCC include KRAS, HRAS, NRAS, and 
PIK3CA, which are involved in the MAPK pathway (Fer-
randiz-Pulido et al. 2015; Silva Amancio et al. 2017; Spiess 
et al. 2016; Wang et al. 2019). However, the mutational sta-
tus of TERT-p was not investigated in that cohort (Ferrandiz-
Pulido et al. 2015). Therefore, further studies on mutations 
coexisting with TERT-p and their significance are needed to 
obtain a deeper understanding of the roles of TERT-p muta-
tions in penile carcinogenesis.
Penile SCCs are pathologically divided into two groups, 
HPV-related and non-HPV-related. The key oncogenic 
mechanism of HPV in humans is its ability to reactivate tel-
omerase, which largely involves the E6 protein of HR-HPV. 
E6 protein directly binds to hTERT and telomeric DNA 
or participates in the epigenetic and post-transcriptional 
Table 2  TERT promoter mutations identified in penile squamous cell carcinoma and control tissues




TERT-p mutant TERT-p wild
Overall c.-146 C > T c.-124 C > T c.-124 C > A c.-139_-138CC > TT
Penile SCC invasive 34 (100%) 15 (44.1%) 11 (32.3%) 3 (8.8%) 1 (2.9%) 0 19 (55.8%)
Penile SCC in situ 3 (100%) 3 (100%) 3 (100%) 0 0 0 0
Penile SCC in situ and invasive 37 (100%) 18 (48.6%) 14 (37.8%) 3 (8.1%) 1 (2.7%) 0 19 (51.3%)
Skin SCC 16 (100%) 10 (62.5%) 8 (50.0%) 1 (6.2%) 0 1 (6.2%) 6 (37.5%)
Pen  NTa 2 (100%) 0 0 0 0 0 2 (100%)
Skin  NTa 2 (100%) 0 0 0 0 0 2 (100%)
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Table 3  Associations between 
TERT promoter mutation and 
clinicopathologic parameters in 
34 patients with invasive penile 
squamous cell carcinoma
Parameters TERT-p wild (N = 19) TERT-p mutant (N = 15) p value
Histologic subtype 0.005*
 HPV-related 12 (63.2%) 2 (13.3%)
 Non-HPV-related 7 (36.8%) 13 (86.7%)
Histologic grade 0.036*
 WD 3 (15.8%) 7 (46.7%)
 MD 5 (26.3%) 4 (26.7%)
 PD 11 (57.9%) 4 (26.7%)
Acantholysis 0.462
 Absent 15 (78.9%) 10 (66.7%)
 Present 4 (21.1%) 5 (33.3%)
Lymphovascular invasion 0.409
 Absent 10 (52.6%) 10 (66.7%)
 Present 9 (47.4%) 5 (33.3%)
Perineural invasion 0.697
 Absent 13 (68.4%) 12 (80.0%)
 Present 6 (31.6%) 3 (20.0%)
Koilocytosis 0.260
 Absent 10 (52.6%) 5 (33.3%)
 Present 9 (47.4%) 10 (66.7%)
Mitosis (/HPF)
 Mean ± SD 9.02 ± 6.92 2.68 ± 1.71
   ≤ 8 10 (52.6%) 15 (100%) 0.001*
   > 8 9 (47.4%) 0 (0%) 0.002*
Tumor thickness (cm) 0.300
  < 1.2 11 (57.9%) 6 (40.0%)
  ≥ 1.2 8 (42.1%) 9 (60.0%)
Necrosis 0.045*
 Absent 7 (36.8%) 11 (73.3%)
 Present 12 (63.2%) 4 (26.7%)
Tumor infiltrating lymphocytes 0.476
 Absent to non-brisk 11 (57.9%) 11 (73.3%)
 Brisk 8 (42.1%) 4 (26.7%)
Ulceration 0.300
 Absent 8 (42.1%) 9 (60.0%)
 Present 11 (57.9%) 6 (40.0%)
Peripheral budding 0.968
 Absent to focal (≤ 10%) 10 (52.6%) 8 (47.4%)
 Diffuse (> 10%) 9 (53.3%) 7 (46.7%)
Intraepithelial microabscess 0.152
 Absent 9 (47.4%) 3 (20.0%)
 Present 10 (52.6%) 12 (80.0%)
T stage 0.679
 1 7 (36.8%) 3 (20.0%)
 2 7 (36.8%) 9 (60.0%)
 3 5 (26.3%) 3 (20.0%)
AJCC stage 0.128
 I, II 11 (57.9%) 13 (86.7%)
 III, IV 8 (42.1%) 2 (13.3%)
LN or distant metastases 0.020*
 Absent 10 (52.6%) 14 (93.3%)
 Present 9 (47.4%) 1 (6.7%)
1131Journal of Cancer Research and Clinical Oncology (2021) 147:1125–1135 
1 3
regulation of hTERT (Katzenellenbogen 2017a, b). In con-
trast, E7 protein can maintain telomere length by the alterna-
tive lengthening of the telomerase pathway, irrespective of 
hTERT. A particularly interesting finding of this study was 
the much higher frequency of TERT-p mutation in non-HPV-
related type of penile SCC, based on both histologic clas-
sification and  p16INK4a immunoreactivity. Although we did 
not investigate the presence of HPV DNA,  p16INK4a immu-
nostaining has been established and widely used as a sur-
rogate marker for transcriptionally active HR-HPV (Aumayr 
et al. 2013; Cubilla et al. 2011). TERT-p mutation was found 
in only 1 of 12 cases with  p16INK4a positivity. In contrast, 14 
of the 22 (63.6%) cases showing negative immunoreactivity 
to  p16INK4a harbored a TERT-p mutation. Similarly, the pres-
ence of differentiated PeIN, which is known to be a non-
HPV-related type of PeIN in the adjacent mucosa, also cor-
related with TERT-p mutation in this study. These results 
suggest two major pathogenetic pathways of penile SCC that 
differ not only with respect to the relation to HPV but also 
with respect to the underlying molecular mechanism, with 
different mechanisms of telomerase activation. We specu-
late that in HPV-related penile SCC, telomerase is activated 
by HPV E6 in the absence of TERT-p mutation, whereas 
mutations of TERT-p might play a role in the mechanism 
of telomerase activation in non-HPV-related penile cancer.
Table 3  (continued) Parameters TERT-p wild (N = 19) TERT-p mutant (N = 15) p value
Tumor size (cm) 0.045*
  ≤ 3 12 (63.2%) 4 (26.7%)
  > 3 7 (36.8%) 11 (73.3%)
Age, years
 Mean ± SD 67.47 ± 13.24 64.27 ± 13.04 0.560
PeIN 0.005*
 Non-HPV-related type 7 (36.8%) 13 (86.7%)
 HPV-related type 12 (63.2%) 2 (13.3%)
HPV human papilloma virus, HPF high-power field, WD well differentiated, MD moderately differentiated, 
PD poorly differentiated, AJCC the American Joint Committee on Cancer, LN lymph node, PeIN penile 
intraepithelial neoplasia
*p < 0.05
Fig. 1  Immunohistochemi-
cal staining for  p16INK4a and 
MIB-1 in penile SCC. a Diffuse 
strong positivity for  p16INK4a in 
TERT-p wild-type penile SCC. 
b  p16INK4a negativity in TERT-
p-mutated penile SCC. c High 
MIB-1 labeling index. d Low 
MIB-1 labeling index
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Based on this assumption, TERT-p mutation is suggested 
as a new potential therapeutic target in non-HPV-related can-
cer. Although penile cancer is typically divided into two 
distinct groups according to clinicopathologic features and 
its relation with HPV, there is no difference in the treat-
ment of these different types, which is mainly due to the 
low prevalence and limited data to understand the detailed 
mechanisms for targeted therapy. In addition, HPV-related 
cancer is known to respond better to radiation or chemora-
diation therapy and shows a more favorable clinical course 
than non-HPV-related cancer (Eich et al. 2020). Therefore, 
further studies are needed to validate our assumption and 
develop targeted therapies for penile carcinoma, especially 
for the non-HPV-related type.
As mentioned above, several previous studies have 
shown associations between TERT-p mutations and 
adverse clinicopathologic parameters or poor prognosis 
in various types of human cancers, including thyroid pap-
illary carcinoma, melanoma, bladder cancer, and glioma 
(Chen et al. 2014a; Griewank et al. 2014; Lee et al. 2015; 
Nasirden et al. 2016; Simon et al. 2015; Wang et al. 2014), 
which was the main motivation for the present study. 
Fig. 2  Kaplan–Meier analysis of the impact of TERT-p mutation on disease-free survival of patients with penile SCC
Table 4  Disease-free survival 
univariate and multivariate 
Cox regression analyses in 34 
patients with penile squamous 
cell carcinoma
HR hazard ratio, CI confidence interval, WD well differentiated, M to PD moderately to poorly differenti-




HR (95% CI) p value HR (95% CI) p value
Histologic grade (WD vs M to PD) 3.01 (0.37–24.20) 0.301
Stage (I, II vs III, IV) 29.37 (3.58–240.87) 0.002* 179.50 (5.37–5997.0) 0.004*
Subtype (HPV vs non-HPV-related) 0.50 (0.13–1.89) 0.311
LV invasion 6.02 (1.24–29.25) 0.026* 0.05 (0.0–0.94) 0.046*
Perineural invasion 4.39 (1.17–16.46) 0.028* 3.65 (0.66–20.13) 0.137
Necrosis 4.67 (1.17–16.46) 0.031* 2.33 (0.46–11.77) 0.308
Mitotic figure (≤ 8 vs > 8 (/HPF)) 2.80 (0.74–10.55) 0.128
MIB-1 LI (≤ 40 vs > 40) 1.99 (0.53–7.50) 0.308
p16INK4a positivity 2.70 (0.71–10.28) 0.147
TERT-p (wild vs mutant) 0.10 (0.01–0.82) 0.032* 0.37 (0.03–4.10) 0.417
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However, in contrast to these previous reports, we found a 
correlation between TERT-p mutation with favorable clin-
icopathologic parameters in penile SCC, including a low 
histologic grade, low mitotic count, absence of necrosis, 
and low MIB-1 index. These results are in line with the 
fact that TERT-p mutations were more frequently detected 
in non-HPV-related tumors, which are generally low-grade 
tumors with low mitotic activities (Steinestel et al. 2015). 
Similarly, the tumors in non-HPV-related penile SCC tend 
to be larger than those in the HPV-related type, which may 
explain the correlation between TERT-p mutant type and 
larger tumor size. Notably, lymph node or distant metas-
tasis rarely occurred in patients with TERT-p mutant type 
of penile SCC; however, further studies in a larger cohort 
will be needed to validate this result. In addition, these 
patients had a significantly longer DFS than patients with-
out TERT-p mutation based on Kaplan–Meier and log-rank 
analysis. In the univariate Cox proportional hazard model, 
the presence of TERT-p mutation was a significant factor 
for predicting longer DFS, but this significant effect was 
not maintained in the multivariate analysis. Instead, clini-
cal stage and lymphovascular permeation were identified 
as independent predictors for DFS. TERT-p mutant type, 
although not significant, accounted for lower stage tumors 
in a large proportion of our cohort and hence could be one 
of the confounding factors for the determination of DFS.
Given the very low incidence of penile carcinoma, this 
study represents a relatively thorough analysis; neverthe-
less, the limitation of this study is its relatively small sam-
ple size, which can be a source of potential bias. There-
fore, further investigations in larger cohorts of patients 
and in vitro studies are needed to validate our results. Our 
study shows that TERT-p mutations are far more frequent 
in non-HPV-related penile SCC based on both histologi-
cal classification and  p16INK4a immunopositivity, and 
offer insight into the pathogenetic mechanisms of this rare 
disease.
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